Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?

被引:1
作者
Kurtaran, Amir [1 ,2 ]
Schmoll-Hauer, Brigitte [1 ,2 ]
Tugendsam, Christina [1 ,2 ]
机构
[1] Krankenanstalt Rudolfstiftung Wien, Nukl Med PET CT & Schilddrusen Kompetenzzentrum, Nukl Med Inst, Juchgasse 25, A-1030 Vienna, Austria
[2] Sigmund Freud Privatuniv, Vienna, Austria
关键词
Differentiated thyroid carcinoma; Individualized treatment; Risk stratification; Radioablation; Active surveillance; RADIOACTIVE IODINE THERAPY; RANDOMIZED CLINICAL-TRIAL; REMNANT ABLATION; PAPILLARY MICROCARCINOMA; SERUM THYROGLOBULIN; ASSOCIATION GUIDELINES; POSTOPERATIVE ABLATION; SUPPRESSION THERAPY; RADIOIODINE THERAPY; ENDOCRINE SURGEONS;
D O I
10.1007/s10354-019-00713-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In recent years, there has been worldwide a significant (relative) increase in "small" thyroid cancer (pT1= tumor size of <= 10mm), which has now reached a plateau. This fact and the absence of prospective and randomized clinical trials are increasingly leading to a discussion of the so-called risk-adapted management of differentiated thyroid cancer. The available studies are partly incomplete, retrospective and difficult to compare. In addition, factors such as different iodine supply, cost-benefit considerations and regional differences in quality of surgical procedures influence the implementation of therapy concepts. Therefore, the therapy of the differentiated thyroid cancer is currently the subject of intensive discussion, especially in "low risk" situations. There is a worldwide trend to classify the risk of differentiated thyroid cancer in general lower than in the past and thus also to reduce the extent of the traditionally recommended therapy. The discussion is increasingly moving from the "one size fits all" towards personalized and thus risk-adapted therapy of the differentiated thyroid cancer. The main goal of this "paradigm shift" is to avoid an "overtreatment" which may be associated with permanent complications due to "unnecessary" surgical procedures and any negative effects of radioiodine ablation. This overview attempts to answer the following questions: When is a risk-adapted therapy for differentiated thyroid cancer justified? What are the consequences in differentiated thyroid cancer if no radioiodine therapy is performed?
引用
收藏
页码:15 / 25
页数:11
相关论文
共 83 条
[51]   Incidental Papillary Microcarcinoma of the Thyroid-Further Evidence of a Very Low Malignant Potential: A Retrospective Clinicopathological Study With Up to 30 Years of Follow-Up [J].
Neuhold, Nikolaus ;
Schultheis, Andrea ;
Hermann, Michael ;
Krotla, Gabriela ;
Koperek, Oskar ;
Birner, Peter .
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (12) :3430-3436
[52]   Papillary microcarcinoma [J].
Noguchi, Shiro ;
Yamashita, Hiroto ;
Uchino, Shinya ;
Watanabe, Shin .
WORLD JOURNAL OF SURGERY, 2008, 32 (05) :747-753
[53]   Analysis of Age and Disease Status as Predictors of Thyroid Cancer-Specific Mortality Using the Surveillance, Epidemiology, and End Results Database [J].
Orosco, Ryan K. ;
Hussain, Timon ;
Brumund, Kevin T. ;
Oh, Deborah K. ;
Chang, David C. ;
Bouvet, Michael .
THYROID, 2015, 25 (01) :125-132
[54]   Prospective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid Cancer [J].
Pacini, Furio .
EUROPEAN THYROID JOURNAL, 2016, 5 (01) :7-+
[55]   Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans [J].
Park, Eun-Kyung ;
Chung, June-Key ;
Lim, Il Han ;
Park, Do Joon ;
Lee, Dong Soo ;
Lee, Myung Chul ;
Cho, Bo Youn .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (02) :172-179
[56]   Importance of tumour size in papillary and follicular thyroid cancer [J].
Passler, C ;
Scheuba, C ;
Asari, R ;
Kaczirek, K ;
Kaserer, K ;
Niederle, B .
BRITISH JOURNAL OF SURGERY, 2005, 92 (02) :184-189
[57]  
Perros P, 2014, CLIN ENDOCRINOL, V81, P1, DOI 10.1111/cen.12515
[58]   Controversies on the Use of Radioiodine in Thyroid Cancer: We Need More and Better Data [J].
Pryma, Daniel A. .
JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (08) :1184-1186
[59]   Number of tumor foci predicts prognosis in papillary thyroid cancer [J].
Qu, Ning ;
Zhang, Ling ;
Ji, Qing-hai ;
Zhu, Yong-xue ;
Wang, Zhuo-ying ;
Shen, Qiang ;
Wang, Yu ;
Li, Duan-shu .
BMC CANCER, 2014, 14
[60]   Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation [J].
Radivoyevitch, T. ;
Sachs, R. K. ;
Gale, R. P. ;
Molenaar, R. J. ;
Brenner, D. J. ;
Hill, B. T. ;
Kalaycio, M. E. ;
Carraway, H. E. ;
Mukherjee, S. ;
Sekeres, M. A. ;
Maciejewski, J. P. .
LEUKEMIA, 2016, 30 (02) :285-294